Lung cancer (LC) is a heterogeneous disease consisting mainly of two subtypes, non-small
cell lung cancer (NSCLC) and small cell lung cancer (SCLC), and remains the leading …

Simple Summary In the past 20 years, the development of targeted therapies that can be
matched to a tumor's molecular and immune abnormalities has resulted in the improvement …

Lung cancer is an uncontrolled and abnormal mass of growing cells with the highest
mortality rate in the world. Progressive lung cancer shows a robust resistance to cancer …

Lung cancer stands as the first cause of death by cancer in the world. Despite the
improvement in patients' outcomes in the past decades through the development of …

Functional genomics is an emerging field focused on elucidating the function of genes or
proteins, which can help solve significant challenges related to reliable cancer therapy. The …

Background Cochrane plain language summaries (PLSs) are an important format to present
high‐quality healthcare evidence to patients with cancer and their families. They should be …

Simple Summary The following paper was developed as a reference for healthcare workers
who are looking for information on advanced non-small cell lung cancers that lack driver …

Abstract Background Lung Adenocarcinoma (LUAD) is a major component of lung cancer.
Endoplasmic reticulum stress (ERS) has emerged as a new target for some tumor …

Lung cancer is a leading cause of global cancer mortality, often treated with
chemotherapeutic agents. However, conventional approaches such as oral or intravenous …

Background: Numerous first-line immune checkpoint inhibitors (ICI) were developed for
patients with advanced non-small cell lung cancer (NSCLC) lacking driver gene mutations …